The average 12-month price objective among analysts that have updated their coverage on the stock in the previous year is $5.61. There is no concrete way to calculate a price target. Piermont Capital Management Inc. increased its stake in shares of Novavax by 9.2% in the third quarter. (NVAX) to Neutral by settling a price target of $1.5 on 9/20/16. They now have a Dollars 25 price target on the stock.
When we have a peek on stock's historical trends we come to know that, the stock has slipped -7.11% in the past one week and plunged -37.37% during previous one month drive, the stock went down -41.78% during past quarter. Ladenburg Thalmann also Downgrade the company to Neutral on 16-Sep-16, 2016. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.
Novavax, Inc. (NASDAQ:NVAX)'s earnings per share has been growing at a -43.4 percent rate over the past 5 year when average revenue increase was noted as 0.9 percent. The 1-year High price of the stock is $8.49, while the 1-year low price is $0.73. Zacks Investment Research upgraded Novavax from a "sell" rating to a "buy" rating and set a $1.75 price objective for the company in a research note on Friday, March 3rd.
Return on Investment measures the amount of return on an investment relative to the investment's cost. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. The company reported the earnings of $-0.21/Share in the last quarter where the estimated EPS by analysts was $-0.23/share.
Maximum and minimum EPS estimate for the current quarter is projected at $-0.13 and $-0.18, respectively, according to 7 analysts. The analysts offering Earnings Estimates for the company were believing that Novavax, Inc. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. (NVAX) is 0 percent. This showed the surprise of 8.7% in the last quarter earnings.
Novavax, Inc. (NVAX) has a market capitalization of 224.24 Million. Overall, 5.75 Million shares exchanged hands versus its average trading volume of 6.23 Million shares.
Novavax, Inc. (NVAX) stock price distance from twenty day simple moving average slumped at -25.87% while its distance from fifty day simple moving average declined -36.36% along with -72.68% below distance from two hundred simple moving averages.
Novavax, Inc. has 1 year price target of $3.58. The firm's 50-day moving average price is $1.28 and its 200-day moving average price is $1.42. On technical aspect, moving averages may help to distinguish path of dispositions, and they may also be used to set degrees of support and resistance.
The company shows its Return on Assets (ROA) value of -56.8%. The return on equity ratio or ROE stands at -329.6 percent while most common profitability ratio return on investment (ROI) was 0 percent. According to their observations and findings, the stock could provide a high EPS of $-0.13/share and a Low EPS of $-0.18/share.
01/18/2017 - Novavax, Inc. had its " rating reiterated by analysts at FBR Capital Markets.
According to sentiments of 6 analysts the company is expected to report revenues of $6.17M for the current quarter. ATR can display volatility of stocks, ETFs and indexes. The Price to Sales (P/S) ratio of the stock is 15.65, while P/B (Price to Book) stands at 0.